PostersScientific Publications Evaluation of a new co-cultured microbiome ecosystem therapy candidate (MaaT034) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors MaaT PharmaMarch 19, 2024
PostersScientific Publications A Multicentre, Randomized, Double-Blinded, Phase 2b Study Evaluating The Efficacy And Safety Of MaaT033, an Oral, Pooled Microbiome Ecosystem Therapy In Patients Undergoing Allogenic Hematopoietic Cell Transplantation to Improve Overall Survival: the PHOEBUS trial MaaT PharmaNovember 13, 2023
PostersScientific Publications Robust Machine Learning (ML) approach for Screening Microbiome Ecosystem Therapies (MET) Drug Candidates in combination with Immune Checkpoint Inhibitors MaaT PharmaOctober 12, 2023
PostersScientific Publications Evaluation of a new co-cultured Microbiome Ecosystem Therapy candidate (MaaT03X) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors MaaT PharmaOctober 12, 2023
PostersScientific Publications Benchmarking of shotgun metagenomics analysis results obtained with state-of-the-art optimized pipelines on simulated gut microbiome samples MaaT PharmaJuly 25, 2023
PostersScientific Publications Restoration of gut microbiota diversity with oral pooled fecal microbiotherapy in acute myeloid leukemia patients after intensive chemotherapy: the phase 1b CIMON trial MaaT PharmaDecember 11, 2022
PostersScientific Publications Pooled allogenic fecal microbiotherapy MaaT013 for the treatment of steroid-refractory gastrointestinal acute graft-versus-host disease: results from the phase IIa HERACLES study and expanded access program MaaT PharmaNovember 13, 2022
Posters Pooling of faecal material results in standardized and high-richness microbiotherapy products MaaT013 and MaaT033 MaaT PharmaNovember 13, 2022
Posters Development of a culture manufacturing process preserving the profile of gut microbiota for therapeutic purposes MaaT PharmaNovember 13, 2022
Posters EBMT 2020: Successful and safe treatment of intestinal Graft-versus-Host Disease (GvHD) with pooled-donor full ecosystem microbiota therapeutics MaaT PharmaAugust 31, 2020
